Shattuck Labs Inc (STTK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$5.15-5.85%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · STTK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.6% |
| Our one-year growth estimate | diamond | -86.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 30.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
STTK — debt issuance
Dated 2026-06-11
Entry into a Material Definitive Agreement. Underwritten Public Offering On June 9, 2026, Shattuck Labs, Inc. (the “Company”) entered into an underwriting agreement (“Underwriting Agreement”) with Leerink Partners LLC, J.P. Morgan Securities LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as the representatives of the underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,879,376 shares of the Company’s common stock, par value $0.0001 per shar…
Why it matters: The company has no product revenue and reported a $15.2 million quarterly loss. Its cash plan funds ongoing trials.
Worry ifA company update moves the cash runway to before 2029, or reports less than $150 million in cash and investments.
Less concerning ifCash and investments stay at or above $150 million, and management keeps its runway guidance into 2029.
Why it matters: Human data would move the second program beyond animal testing. A missed start would leave the plan behind schedule.
Supportive ifThe company confirms the SL-846 Phase 1 trial starts in the first half of 2027.
Worry ifThe company delays the Phase 1 start beyond June 30, 2027, or reports that the trial has not started.
Why it matters: The next results are a near-term check on trial timing and cash. The latest company update gave no new proof of patient enrollment.
Watch forThe November 5 update confirms RECEPTIVE-CD1 has started. Cash can last into 2029.
Also watch forThe update reports a delayed trial start or cuts runway guidance to before 2029.
Why it matters: The toxicology data are a key step before human testing. A safety concern could slow the program.
Watch forThe October 17–20, 2026 poster reports no major safety issue in the primate study.
Also watch forThe poster reports a major safety concern, or the data are not shown by October 20, 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$278 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $644 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,051 loss on $10,000 · 50.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.